Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery-1

Abstract

Trophoresis before (lanes 1,3) or after (lanes 2,4) depletion for abundant proteins by cibacron blue and detected by coomassie blue straining. B-C: Control- and ovarian cancer-pool serum depleted for abundant sequences were immunoprecipitated with biobodies selected for specific binding to case-pool serum. The products of elution from control sera (B lane 2, and C) and ovarian cancer (B lane 1, and D) were separated by 1-D (B) or 2-D (C,D) protein electrophoresis and detected by silver staining. In the 2-D gels, the immunoprecipitates were focused over a pH3 to pH10 range and run on a 10% acrylamide gel. The circle indicates the region where PEBP1 was found in patient serum (D) but not in control serum (C).<p><b>Copyright information:</b></p><p>Taken from "Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery"</p><p>http://www.translational-medicine.com/content/6/1/41</p><p>Journal of Translational Medicine 2008;6():41-41.</p><p>Published online 24 Jul 2008</p><p>PMCID:PMC2503970.</p><p></p